Nov 12, 2025 08:00AM
Nov 6, 2025 08:00AM
Nov 6, 2025 08:00AM
Oct 14, 2025 07:00AM
Oct 14, 2025 07:00AM
Oct 8, 2025 08:00AM
Oct 8, 2025 08:00AM Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema
Oct 2, 2025 08:00AM
Oct 2, 2025 08:00AM
Sep 17, 2025 08:00AM
Sep 17, 2025 08:00AM
Aug 12, 2025 04:10PM
Aug 6, 2025 08:01AM
Aug 6, 2025 08:00AM Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan
Jun 13, 2025 07:00AM
Jun 13, 2025 07:00AM
May 13, 2025 04:10PM
May 1, 2025 08:03AM
May 1, 2025 08:00AM
Mar 11, 2025 08:00AM
Feb 27, 2025 08:00AM Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema
Jan 23, 2025 08:00AM
Jan 13, 2025 08:03AM
Jan 13, 2025 08:00AM
Dec 11, 2024 08:00AM
Dec 10, 2024 08:08AM
Dec 10, 2024 08:00AM
Nov 13, 2024 04:10PM Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Oct 16, 2024 08:05AM
Oct 16, 2024 08:00AM
Sep 30, 2024 08:01AM
Sep 30, 2024 08:00AM
Aug 12, 2024 04:10PM
Aug 12, 2024 04:01PM
Aug 12, 2024 04:00PM Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema
May 9, 2024 04:10PM
Apr 9, 2024 08:21AM
Apr 9, 2024 08:00AM
Mar 25, 2024 07:31AM
Mar 25, 2024 07:30AM
Mar 4, 2024 04:10PM
Nov 27, 2023 08:00AM Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress
Nov 13, 2023 08:00AM
Nov 10, 2023 08:00AM
Nov 3, 2023 08:10AM
Oct 11, 2023 05:10PM
Aug 31, 2023 08:01AM
Aug 31, 2023 08:00AM
Aug 7, 2023 04:10PM Astria Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update
Jul 20, 2023 08:01AM

322,207 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All